Jounce Therapeutics — Investor Presentation (January 2020)
26 slides from Jounce Therapeutics's investor presentation, Jan 13, 2020
Slide 1: Jounce Therapeutics: A Next Gen Immunotherapy Company
Jounce Therapeutics A Next Gen Immunotherapy Company
Slide 2: Legal Disclaimer
Legal Disclaimer Various statements concerning Jounce’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding the timing, progress and results of discovery programs, preclinical studies and clinical trials for Jounce’s product candidates and any futu
Slide 3: Jounce: Our Approach
Jounce: Our Approach Novel Discovery Development Moving Beyond Today’s The right immunotherapies Immunotherapies for the right patients 3 | Jounce Therapeutics, Inc. © January 2020
Slide 4: The Jounce Difference
The Jounce Difference Clinical Stage IO Pipeline • Vopratelimab: ICOS Agonist in Phase 2 – Two development paths, guided by clinical data and biomarkers – EMERGE preliminary efficacy data in 2H20 • JTX-4014: Phase 2 ready PD-1 Inhibitor (PD-1i) – First use in combo with vopra in SELECT Translational
Slide 5: The Core of Our Approach: Translational Science Platform
The Core of Our Approach: Translational Science Platform Translational Drug Discovery Reverse Translational Analysis • Sustainable engine for 1st in class • Patients with clinical outcomes • Focused on multiple immune cell • PD* and predictive biomarkers types • Patients more likely to respond *PD=
Slide 6: Jounce Immunotherapy Pipeline
Jounce Immunotherapy Pipeline Preclinical Clinical Program Target Biology Discovery IND Enabling Phase 1 Phase 2 Phase 3 Development Programs CD4 T cell Vopratelimab ICOS focused CD8 T cell JTX-4014 PD-1 focused Suppressive JTX-8064 LILRB2 macrophage Not JTX-1811 T-regulatory Disclosed Discovery Pro
Slide 7: Development Programs
Development Programs Vopratelimab JTX-4014 JTX-1811
Slide 8: Vopratelimab Harnesses a Different Element of the Immune Response
Vopratelimab Harnesses a Different Element of the Immune Response Mechanism of Action on CD4 T Cells, from Clinical Data Activation of ICOS lo to Vopra Stimulates ICOS hi but Potential for Clinical Benefit ICOS hi CD4 T Cells not ICOS lo CD4 T Cells ICOS ICOS Vopratelimab Vopratelimab Cancer Antigen
Slide 9: Vopratelimab Value Proposition
Vopratelimab Value Proposition BiologicalBiological activity activity beyond distinct CD8 from focused CD8 focused PD-1 inhibitors PD(L)-1i* Biomarker driven development paths based on clinical data Key Learnings from ICONIC** Lead to Changes in New Ph 2 Studies • Peripheral ICOS hi CD4 T cells as a
Slide 10: Clinical Benefit Correlates with ICOS hi CD4 T Cells
Clinical Benefit Correlates with ICOS hi CD4 T Cells Vopratelimab, but not PD-(L)1i, Causes Emergence of ICOS hi CD4 T Cells* Tumor Reduction Tumor Change from Baseline 100 Data cut-off 10-DEC-2019 75 Data cut-off 10-DEC-2019 All patients with evaluable samples and tumor measurement, n = 46 50 25 %
Slide 11: Clinical Benefit Correlates with ICOS hi CD4 T Cells: ICONIC
Clinical Benefit Correlates with ICOS hi CD4 T Cells ICONIC Clinical Benefit: ICOS hi vs. ICOS lo CD4 T Cells* ICOS hi (n=18) ICOS lo (n=32) RECIST 1.1 ORR 4 (22.2%) 0 Median PFS 6.2 months 2 months Median OS 20.7 months 9 months Progression Free Survival Overall Survival Data cut-off 10-DEC-2019, c
Slide 12: ICONIC Data Leads to Unique Dosing Strategy
100 t n e 80 m saturation of receptor ICONIC Data Leadse to Unique Dosing Strategy g a 60 g n E saturation of signaling t 40 Target Engagement from ICONIC Patients e g r a 0.03 mg/kg vopra + ipi T 20 100100 t % t 0.1 mg/kg vopra + ipi n n Dose used in ICONIC: e e 0 80 80 0.3 mg/kg vopra + ipi m m 0
Slide 13: Reverse Translational Work Leads to Two Development Paths
Reverse Translational Work Leads to Two Development Paths Inducer Combinations Predictive Biomarker Prioritize combinations with Use baseline biomarker to agents that induce predict ICOS hi CD4 T cell ICOS hi CD4 T cells emergence by vopra CTLA-4i + CTLA-4i Vopratelimab Vopratelimab + JTX-4014 Vopra
Slide 14: Vopratelimab Phase 2 EMERGE Study: Combo with Ipilimumab
Vopratelimab Phase 2 EMERGE Study: Combo with Ipilimumab Phase 2 EMERGE Study – Initiated June 2019 • PD(L)-1i experienced NSCLC – high unmet need – Standard of Care: docetaxel – Two 20 patient dose cohorts; first fully enrolled, second enrolling – Endpoints: ORR, DCR, DOR, PFS, OS, safety – Clinica
Slide 15: Baseline RNA Signature Predicts ICOS hi CD4 T Cells and Clinical Benefit
Baseline RNA Signature Predicts ICOS hi CD4 T Cells and Clinical Benefit ICOS hi CD4 T Cells: RNA Signature (RS) Predicts Emergence RS Predicts Overall Survival Vopra PD Biomarker (Treatment Emergent) of ICOS hi CD4 T Cells Overall Survival: ICONIC Patients with Longitudinal T Cells Overall Survival
Slide 16: SELECT: Phase 2 Biomarker Study
SELECT: Phase 2 Biomarker Study Phase 2 SELECT Randomized Study • IO naïve 2L NSCLC in ~75 patients (ex-US) • Patients selected with RNA signature, optimized to predict for ICOS hi CD4 T cells • Estimate ~20% of 2L NSCLC patients above biomarker cut-off • Interim clinical data expected in 2021 Trial
Slide 17: Development Programs
Development Programs Vopratelimab JTX-4014 JTX-1811
Slide 18: JTX-4014: Phase 2 Ready PD-1 Inhibitor
JTX-4014: Phase 2 Ready PD-1 Inhibitor Well-Characterized PD-1 Antibody, Fully Human IgG4 Target Lesion Change from Baseline Over Time Phase 1 Study Results • Late stage IO naïve patients, median 4.5 Data cut-off 19-SEP-2019 lines of prior therapy • No deaths or dose limiting toxicities • 3/18 (16.7
Slide 19: Development Programs
Development Programs Vopratelimab JTX-4014 JTX-1811
Slide 20: JTX-1811: Designed to Deplete Immunosuppressive T regulatory Cells
JTX-1811: Designed to Deplete Immunosuppressive T regulatory Cells • T regulatory cells (T regs) • JTX-1811 is a monoclonal – Diminish productive immune responses antibody designed to deplete – Immune response to tumors may require T regs in the tumor reducing T regulatory effect microenvironment JT
Slide 21: JTX-1811: Target Specificity to T regs in the Tumor
JTX-1811: Target Specificity to T regs in the Tumor JTX-1811 Selectively Binds to T regs from TILs* Peripheral Blood** Lung Tumor** (Healthy) Similar binding to T regs from multiple Tregs Tregs tumor types (n=25) including: Tconv Tconv Iso Iso • NSCLC • Breast • Colon • Head & Neck Cell Count Cell •
Slide 22: Single Agent Anti-Tumor Activity in PD-1 Inhibitor Resistant Tumors
Single Agent Anti-Tumor Activity in PD-1 Inhibitor Resistant Tumors Also Restores PD-1i Activity PD-1 Inhibitor Resistant Mouse Tumor Models Selective Depletion of Tumor T regs Colon-26 Tumor MBT-2 Tumor Tumor Resident Immunosuppressive T regs 5/10 complete responder 5/9 complete JTX-1811 responder
Slide 23: The Jounce Approach: Sustainable Discovery for 1st in Class Immunotherapies
The Jounce Approach: Sustainable Discovery for 1st in Class Immunotherapies Translational Science Platform Innovative & Sustainable Discovery Pipeline Immunosuppressive T regulatory cells Inhibit immunosuppressive activity Stromal cells Approach for cold tumors that lack T cells New target ID from 1
Slide 24: Financial Strength and Flexibility
Financial Strength and Flexibility Financial Overview Funding History NASDAQ: JNCE Event Date Gross $ Comment Series A 2013 $47M Third Rock Strong balance sheet: Ventures • $185.1M cash and investments, Series B 2015 $56M Fidelity, as of September 30, 2019 Wellington, others Updated Financial guidan
Slide 25: Milestones
Milestones 2019 2020 ▪ Three immunotherapies in the clinic ▪ Vopratelimab: Preliminary efficacy and related ✓ Two wholly owned immunotherapies in the biomarker data from EMERGE in 2H20 clinic ▪ Vopratelimab + JTX-4014: Initiation of predictive ✓ Exclusively out-licensed JTX-8064 biomarker SELECT stu
Slide 26: Jounce Therapeutics: A Next Gen Immunotherapy Company
Jounce Therapeutics A Next Gen Immunotherapy Company
Jounce Therapeutics — Investor Presentation (January 2020) on 6ix